Drug developers working in infectious diseases, oncology, autoimmune and advance modalities like cell and gene therapy, ADCs, RNA therapeutics (mRNA/RNAi) increasingly face a familiar challenge: the assays they need often don’t yet exist. Off‑the‑shelf solutions rarely answer the specific mechanistic questions regulators ask, and standard diagnostic platforms offer little room for adaptation. As therapeutics become more complex, the tools required to evaluate them must evolve just as quickly.
That’s where custom assay design becomes essential. It’s not simply a technical exercise — it’s a form of scientific problem‑solving that blends creativity, regulatory awareness, and deep understanding of the mechanism of action. And it’s becoming one of the most important ways to de‑risk early‑phase development.
Understanding the Question Behind the Question
Every custom assay begins with a problem. A sponsor approaches with a therapeutic concept, a mechanism of action, and a regulatory question they need to answer. Sometimes they know they need a bespoke assay; more often, they don’t. They arrive with a challenge — “How do we demonstrate this effect?” or “How do we satisfy this regulatory concern?” — and the work begins by unpacking what the regulator is really asking.
That requires fluency in three domains:
Only by holding all three in view a team can design an assay that is scientifically rigorous, regulator‑ready, and genuinely fit for purpose.
Building a Tool That Doesn’t Yet Exist
Custom assay development is, at its core, engineering. It involves sourcing or designing reagents, defining detection strategies, modelling kinetics, and building the analytical framework that will ultimately interpret the data. But it also requires something less tangible: creativity.
Creativity in science isn’t improvisation — it’s the ability to think beyond the obvious, to draw on years of accumulated experience, and to combine insights from different disciplines. It’s built through exposure to diverse scientific communities, literature, and methodologies. And it’s essential when the question being asked has no standard answer.
One recent example illustrates this well. Regulators raised a concern that an antiviral treatment might suppress the production of a specific subset of neutralising antibodies. The sponsor needed a way to demonstrate whether that effect was occurring. No existing assay could answer the question directly. The solution required designing a new tool from the ground up: identifying the right reagents, defining the detection strategy, modelling the expected physiological response, and building the informatics needed to interpret the results. The final assay was precise, validated, and tailored to the regulatory question — exactly what the programme needed to move forward.
Not Off‑the‑Shelf — and Not Niche
Custom assays are sometimes misunderstood as niche or specialised tools reserved for unusual programmes. In truth, they are becoming a standard requirement for early‑phase development, especially when working with novel mechanisms or advanced modalities. While off‑the‑shelf assays still play an important role — particularly for clinical and regulatory comparability — they cannot answer every question.
A tailored assay, once developed and validated, becomes a durable asset. It can support exploratory endpoints in early studies, carry through into Phase II, and in many cases, remain relevant into later phases. It gives developers a consistent, scientifically grounded way to measure what matters most for their therapeutic.
A Collaborative, Creative Process
Although assay design often begins with a single scientist, it rarely ends there. The most effective solutions emerge from collaborative thinking — a community of experts bringing different experiences, perspectives, and technical strengths. One person may contribute deep knowledge of viral kinetics, another expertise in immunology, another in data interpretation or informatics. Together, they build something no single individual could have produced alone.
This collaborative creativity is what allows teams to respond to unusual regulatory questions, adapt to emerging therapeutic modalities, and design tools that are both scientifically robust and operationally practical.
Reducing Risk, Increasing Confidence
Custom assay design is more than a laboratory exercise. It’s a strategic tool for reducing uncertainty early in development. When sponsors can answer regulators’ questions with precision, they move forward with greater confidence. When investors see a clear, scientifically grounded plan for measuring efficacy or safety, they gain trust in the programme. And when assays are designed with regulatory expectations in mind from the outset, the path to IND or IMPD becomes smoother and more predictable.
Crucially, effective custom assay development spans multiple technologies and analytical platforms — from cell‑based systems to ligand‑binding and molecular assays — each selected to align with the therapeutic’s mechanism of action. Building the right tool often requires integrating these approaches, which makes a capable laboratory partner with strengths across disciplines an essential part of the process. The broader the technical foundation, the more precisely an assay can be engineered to answer the specific questions regulators and developers care about.
In a landscape where therapeutics are becoming more complex and regulatory expectations more specific, custom assay development is no longer optional. It’s a critical capability — one that blends scientific creativity, cross‑platform expertise, and rigorous engineering to deliver the clarity modern drug development demands.
Author: Elisa Masat
Sign up to our emails and follow us on social media to keep up to date with hVIVO.
